Genezen was founded to serve as a trusted partner between therapeutic companies and academic vector cores and has since undergone a remarkable evolution, emerging as a leading provider of viral vector manufacturing services for gene and cell therapies.

Our Journey

We embrace innovation and are steadfast in our resolve to deliver customer projects on time and in full to ensure our customers can meet their clinical trial timeline commitments.

2014-2020

Foundation & Early Years

In 2014, our founder, Bill Vincent, laid the cornerstone for Genezen. By 2015, we had formed pivotal partnerships with Cincinnati Children’s Hospital and Indiana University, thus setting the stage for our journey into GMP-grade viral vector development and making us a vital player among viral vector manufacturing companies.

2022

GMP Production

Genezen completes 25,000 ft2 expansion for lentiviral and retroviral GMP facility, complementing our process development, analytical development, and GMP cell banking. This expansion bolstered our commitment to excellence by allowing us to launch AAV contract manufacturing services.

2024 & Onward

Future Developments

Committed to technological and capacity advancements, Genezen is continuing construction on 75,000 total ft2 of state-of-the-art facilities. Simultaneously, we are conducting studies to assess the effectiveness of novel technologies, solidifying our position as leaders in viral vector CDMO services, including lentiviral vector production services and lentiviral gene therapy companies.

Our Mission

Our Mission: To drive the advancement of gene and cell therapies by providing science-driven development and manufacturing solutions.

We are a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral vector, and adeno-associated viral (AAV) vectors. We drive the advancement of gene and cell therapies by providing science-driven development and manufacturing solutions — a mission that unites our team as we work diligently to bring your gene or cell therapy successfully to clinic.

Meet Our People

Our team is dedicated to getting your viral vector where it needs to go. Communication and collaboration are part of our DNA and we can’t wait to talk to you about your current challenges and needs.

Steve Favaloro, CEO of Genezen, a viral vector CDMO for cell and gene therapy.

Steve Favaloro

Chairman and Chief Executive Officer
Susan D’Costa, Chief Technical Officer at Genezen, expert in viral vector manufacturing.

Susan D’Costa, PhD

Chief Technical & Commercial Officer
Steve Favaloro, CEO of Genezen, a viral vector CDMO for cell and gene therapy.

Steve Favaloro

Chairman and Chief Executive Officer
Susan D’Costa, Chief Technical Officer at Genezen, expert in viral vector manufacturing.

Susan D’Costa, PhD

Chief Technical & Commercial Officer
Genezen team members working on viral vector generation services to advance patient therapies

Explore careers at Genezen

We are continuously in the pursuit of world-class talent. Do you have a passion for promoting scientific advancement? Are you hungry to grow alongside and help shape a fast-developing, science-led CDMO? You may be a perfect fit for Genezen.

Get insights like this directly to your inbox.

Sign up for the latest Genezen news and updates.